Fig. 5

Genetic deletion or pharmacological inhibition of HDAC3 promotes the acetylation and degradation of GATA3. A Representative Western blot images and the corresponding quantitative results of KLF4, HIF-α, GATA3, c-Jun and BRD4 in PBS-treated or TGF-β1 treated primary AT2 cells from HDAC3-C and HDAC3-CKO mice for 72 h. (n = 5). B The relative mRNA expression of GATA3 in PBS-treated or TGF-β1 treated primary AT2 cells from HDAC3-C and HDAC3-CKO mice for 72 h. (n = 5). C, D Protein degradation assay. Representative Western blot images and corresponding quantitative results for GATA3 in AT2 cells following treatment with cycloheximide (250 μg/ml) for 0, 1, 2, 4, 6, 8 h after genetic (HDAC3 deficiency in AT2) or pharmacological (RGFP966, 15 μM) inhibition of HDAC3. (n = 3). E The acetylation level of GATA3 in AT2 was determined by Co-IP experiments after genetic (HDAC3 deficiency in AT2) or pharmacological (RGFP966 for 4 h, 15 μM) inhibition of HDAC3. (n = 5). (*P < 0.05, **P < 0.01, ***P < 0.001, ^nsP > 0.05. M refers to protein marker)